| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
PEGs Alkyl/ether
PROTAC Linkers. |
|---|---|
| ln Vitro |
One ligand is for an E3 ubiquitin ligase, and the other is for the target protein; these two ligands are joined by a linker to form PROTACs. The intracellular ubiquitin-proteasome system is utilized by PROTACs to specifically destroy target proteins[1].
As a PEGylation reagent, m-PEG-NHS ester (MW 5000) itself has no intrinsic biological activity; it is used to modify amines on proteins, peptides, or small molecules to improve their physicochemical and pharmacokinetic properties. The NHS ester group reacts with primary amines to form stable amide bonds. The large PEG5000 chain provides a hydrophilic shield that can reduce protein aggregation, decrease immunogenicity, and prolong circulation half-life by reducing renal clearance and protecting against proteolytic degradation. In PROTAC research, this reagent can be used to PEGylate a target protein ligand or an E3 ligase ligand to improve its solubility and stability before incorporation into a PROTAC. Alternatively, it can be used to PEGylate a complete PROTAC molecule to enhance its pharmacokinetic properties. |
| ln Vivo |
No specific in vivo activity has been reported for this PEGylation reagent alone; its activity is derived from the final PEGylated conjugate.
|
| Enzyme Assay |
N/A; this compound is not assessed in isolated enzyme/receptor binding assays. As a PEGylation reagent, its quality is typically confirmed by analytical methods such as HPLC and NMR. The molecular weight distribution (polydispersity) of the PEG5000 chain is typically characterized by GPC or MALDI-TOF mass spectrometry. The NHS ester content is typically determined by titration or by UV absorption (260 nm). The compound is often used as a reference standard.
|
| Cell Assay |
N/A; this linker is not tested alone in cell-based assays. In a typical PEGylation reaction, the NHS ester is reacted with a primary amine-containing molecule (e.g., a PROTAC molecule, a target protein ligand, or an E3 ligase ligand) in a buffer such as PBS (pH 7.4) at room temperature for 1-4 hours. The PEGylated product is then purified and tested in cells for its biological activity. For example, PEGylation of a PROTAC may improve its cellular uptake or reduce non-specific binding. The effect of PEGylation on target degradation activity is assessed by Western blotting.
|
| Animal Protocol |
N/A; no animal studies are performed with the PEGylation reagent alone. For a PEGylated conjugate, in vivo studies are conducted following institutional guidelines. The high molecular weight PEG5000 chain is expected to significantly prolong the circulation half-life, reduce immunogenicity, and improve the pharmacokinetic properties of the conjugate. The PEGylated conjugate is typically formulated in a suitable vehicle (e.g., PBS) and administered via intravenous (IV) injection.
|
| ADME/Pharmacokinetics |
This compound has a molecular weight of approximately 5000 Da (average molecular weight, polydisperse). The molecular formula is (C2H4O)nC7H9NO5, where n is the number of ethylene glycol units (approximately 114). It appears as a white to off-white solid. For storage, it should be kept as a powder at -20degC for up to 3 years or at 4degC for up to 2 years, sealed, away from moisture. It is soluble in DMSO, water, and other organic solvents. The product should be stored under nitrogen to prevent moisture absorption, as the NHS ester is moisture-sensitive. CAS: 92451-01-9. Other names: methoxypolyethylene glycol 5,000 acetic acid N-succinimidyl ester; mPEG-SC (MW 5000); mPEG-Succinimidyl ester (MW 5000).
|
| Toxicity/Toxicokinetics |
This product is for research use only and is not for human or veterinary use. Standard chemical safety precautions should be observed during handling. The NHS ester is moisture-sensitive and should be handled in a dry environment. It is not an approved therapeutic drug and has not been cleared for clinical use. It is a PEGylation reagent for research and development purposes only.
|
| References | |
| Additional Infomation |
The high molecular weight PEG5000 chain provides a dense hydrophilic corona that effectively shields the conjugated molecule from the immune system and reduces renal clearance, making it ideal for extending the circulation half-life of therapeutic proteins and nanoparticles. In PROTAC research, PEGylation can be used to improve the solubility and pharmacokinetic properties of PROTACs, which often suffer from poor aqueous solubility and rapid clearance. This reagent is also widely used in the preparation of PEGylated liposomes, nanoparticles, and other drug delivery systems. The NHS ester provides a versatile conjugation handle for attachment to any primary amine-containing molecule, including lysine residues on proteins and N-termini of peptides.
|
| Molecular Formula |
(C2H4O)NC7H9NO5
|
|---|---|
| Molecular Weight |
5000(Average)
|
| Exact Mass |
293.111
|
| CAS # |
92451-01-9
|
| PubChem CID |
71312614
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
20
|
| Complexity |
275
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COCCO.OCCOCC(ON1C(=O)CCC1=O)=O
|
| InChi Key |
NYXRHTOXAYVBMV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H11NO6.C3H8O2/c10-3-4-14-5-8(13)15-9-6(11)1-2-7(9)12;1-5-3-2-4/h10H,1-5H2;4H,2-3H2,1H3
|
| Chemical Name |
(2,5-dioxopyrrolidin-1-yl) 2-(2-hydroxyethoxy)acetate;2-methoxyethanol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
